Japan Feb drug sales -2.9%, says Crecon

30 April 2001

Japanese sales of pharmaceutical products declined 2.9% in February ofthis year, compared with the like 2000 month, while turnover of ethical drugs and over-the-counter medicines decreased 2.4% and 12.1% respectively, according to Crecon Research & Consulting.

The downturn was attributed to the lack of a serious flu season and less hay fever. Also contributing to the downward trend, reports Pharma Japan, was the fact that the price agreement rate, which remained lower than in ordinary years until January, picked up briskly in February, resulting in sales price falls compared to the prices temporarily set at the time of delivery. Cumulative drug sales from April 1, 2000 through February 2001 increased 2.4% (ethical drugs up 2.7% and OTC medicines down 1.4%).

Generic viewed poorly by pharmacists

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight